Ecovadis Assessment

...), 에코바디스(EcoVadis) 등 주요 글로...석한 LCA(Life Cycle Assessment) 제출을 요구...

... 에코바디스(Ecovadis)에서 2년 연...여 평가(Supplier Engagement Assessment, SEA)에서 최고...성평가(Corporate Sustainability Assessment, CSA)에서도 자...

Part 1: Our experience Our medium sized EU based company recently went through an EcoVadis assessment. Paid for it, filled everything out, uploaded all the documentation we had. Actual policies, actual certificates, things we genuinely have in place as a real functioning company under EU legislation. Got a poor score. Multiple indicators at 0/100. Turned out our documents were just never evaluated. We uploaded them in our native language through their own “Other language” option, because not every company in EU operates in English. Nobody reached out asking for translations, nobody flagged anything. The system just ignored them and scored us accordingly. We contacted support. They told us the Corrective Action Plan we had already submitted doesn’t actually impact the scorecard. Cool, so what is it for? Kept pushing and eventually found out through someone else who went through the same thing that there’s actually no human reviewing your documents at all. It’s fully automated. The bot doesn’t recognize something, it skips it. Wrong language, unfamiliar format, doesn’t matter. You just get a 0 and nobody tells you why. Part 2: The bigger problem EcoVadis has a complete quasi-monopoly on B2B sustainability assessments in the EU. Hundreds of major corporations like Siemens, L’Oréal and Nestlé require it from their suppliers. You don’t choose EcoVadis. Your client chooses it for you. Pay or lose the contract. And yet EcoVadis itself is accountable to no one. No EU body audits their methodology. No standard governs how they evaluate documents. No regulator checks whether their automated system is actually accurate. We’re building an entire regulatory framework in the EU around ESG, CSRD, and supply chain due diligence, all of which in practice creates a captive market for companies like EcoVadis. Small and mid-size suppliers across Europe are paying hundreds of euros, submitting real documentation, and getting scored by a black-box algorithm with no meaningful appeals process and no transparency. If an EU regulation required us to submit inaccurate data, we faced consequences. EcoVadis submits inaccurate assessments to our clients and calls it a service. If this is what EU sustainability compliance looks like in practice, what exactly are we building here? submitted by /u/MS_Fume to r/europeanunion [link] [comments]

submitted by /u/Quantisnow to r/Quantisnow [link] [comments]

Since the emergence of the legal cannabis industry across the Western world, operators have persistently been forced to deal with an issue faced by few counterparts in established sectors: they can’t get insured. In the UK, we’ve reported on firms seeing their bank accounts closed overnight with no explanation, facing rejections for even basic employer liability coverage, and facing fines of up to £2500 a day for operating without protection. Similar stories extend throughout Europe, while US operators facing ongoing federal prohibition remain exposed to risks every other sector can easily insure against, such as product liability, theft, crop failure, and workplace injuries. According to Claire Davey, Senior Vice President of Product Innovation and Emerging Risk at Relm, whose team co-authored a new Risk Briefing on the cannabis sector with Prohibition Partners, this dynamic is now beginning to change. “Compared to Europe, the US and Canadian insurance market has facilitated greater access to insurance for operators, during the last 2-3 years, particularly for relatively commonplace (yet necessary) coverages, such as Directors and Officers Liability, due to relative market maturity,” she told Business of Cannabis. Despite improvements, cannabis remains a notable outlier in terms of access to insurance coverage. According to the recently published report, however, insurance challenges are now less about whether insurance capital is available but more about whether operators are professionalised enough to secure it. Join Relm and Prohibition Partners on Wednesday, February 04, at 3pm, for a live webinar unpacking the key findings from the Risk Briefing: Cannabis 2026 report. The session will explore where risk concentrations are highest across the cannabis supply chain, why contamination continues to drive recalls, and what leading operators are doing to strengthen governance and reduce exposure. What underwriters actually demand According to Davey, the barriers to comprehensive coverage are twofold. “With respect to the US, it is regulatory uncertainty and the lack of governance around particular risk exposures. “Insurers are highly regulated businesses, and they often need greater certainty regarding legality. They also want to be clear on how insureds are managing their risk.” For European and international markets, ‘the regulatory concern is paired with the lack of size and maturity of the cannabis industry, which has not yet reached enough of a critical mass to convince insurers of committing to the opportunity.’ The Relm Risk Briefing, which draws on interviews with leading operators like Glass Pharms, Linnea, SOMAÍ Pharmaceuticals, and PHCANN International, explores the dramatic variations in what underwriters look for depending on coverage type. Product Liability insurers are ‘keen to see internationally recognised quality assurance certifications that are achieved and maintained’. In practice, this means EU-GMP certification is critical, given that few jurisdictions offer full alignment with Good Manufacturing Practice standards, and contamination risks persist throughout the supply chain. For Crime insurance covering theft of crops and assets, ‘insurers are looking to see that a range of physical, logical and technical controls are implemented.’ Between 2018 and 2022, Canadian licensed producers reported over 2200 kg of cannabis as missing or stolen, with most incidents during transportation. Meanwhile, for D&O (Directors and Officers) coverage, the focus shifts to governance fundamentals. “What do their financials show? How is the business managing regulatory risk? What are they communicating to investors and how are they delivering on this?” This scrutiny reflects genuine exposure. Canopy Growth Corp., one of the largest publicly traded cannabis companies, currently faces a class action lawsuit alleging misleading statements about production costs. Insurance as driver, not just an indicator Davey argues that the relationship between insurance and operational excellence extends beyond simple risk transfer, with the process of applying for insurance ‘encouraging a business to reflect on, and provide evidence of, its governance practices and risk reduction strategies’. “If the application for insurance suggests that risk posture is weak, or it is lacking data transparency, the operator needs to improve this in order to avoid the withdrawal of insurance coverage or the increased premiums and retentions that may result from poor risk management. Thus, insurers are often pushing for best practices, and encouraging and rewarding such improved postures.” The report’s risk mitigation strategies span the entire supply chain. In cultivation, controlled environments, tissue culture, genetics for consistency, and integrated pest management demonstrate operational maturity that insurers reward. Glass Pharms CEO James Duckenfield notes: “Seeds proved too variable, so we use only tissue culture genetics for consistency.” In manufacturing, where, for example, a January 2025 explosion at PharmaCann’s Maryland extraction facility caused over $250,000 in damages, insurers demand strict safety protocols and facility controls. For distribution, where temperature excursions threaten product integrity, operators need GDP-aligned transport with data loggers and comprehensive cargo insurance. Linnea CEO Susanne Caspar said: “We always advise clients to have door-to-door coverage, regardless of Incoterms, to avoid disputes between buyers and sellers.” ​​Future-Ready: Why Pure Is Building the Cannabis Company Traditional Industry Will Want to Buy Into Read More » February 5, 2026 No Comments Germany’s Cannabis Future: Political Posturing vs. Market Reality Read More » February 5, 2026 No Comments Insurance Has Become a Critical Benchmark for Cannabis Industry Maturity Read More » February 3, 2026 No Comments Inadequate coverage and its costs The report also explores incidents illustrating the financial consequences of inadequate risk management and insurance. River Valley Growers in Massachusetts lost its entire 2022 harvest, valued at $7 million, when pesticide drift from a neighbouring farm contaminated their crop. The cultivator went out of business, unable to meet production contracts. C&C Manufacturing LLC in Missouri had its license revoked after creating a distillate with unregulated THC levels, triggering a statewide recall of 135,000 products in 2024. Elsewhere, NNK Equity LLC in New Mexico faced seizure and destruction of tens of thousands of plants worth hundreds of thousands of dollars after failing multiple compliance requirements, including inadequate security and track-and-trace violations. These incidents illustrate that operators who treat insurance as an administrative burden rather than good risk management discipline leave themselves exposed not just to claim denials but to the underlying operational failures that trigger claims. The European opportunity While North American markets face saturation and regulatory uncertainty, Europe presents a different trajectory. “We would expect that there will be an expansion of insurance capacity for the European cannabis markets over the coming years,” Davey suggests. “The US and Canada are already relatively saturated, although the US’s move towards rescheduling may make this even more prominent. The respective European approaches to deregulation—which are quite steady and measured—offer a greater degree of certainty and confidence that enable insurers to plan for, and mobilise over the medium to longer term.” Europe’s total cannabis sales are forecast to grow from $1.5 billion in 2025 to $3.3 billion by 2030, driven by permanent frameworks in Denmark and France, market expansion in the UK and Germany, and broader adoption. The pharmaceutical focus, emphasising GMP facilities, pharmacy distribution, and prescription-based access, provides the regulatory clarity insurers need. Germany offers public health insurance reimbursement, a stability factor appealing to underwriters. France’s transition from pilot program to generalised medical access in April 2026 represents the measured regulatory evolution. Spain, Slovenia, Ukraine, and Bosnia and Herzegovina are developing frameworks prioritising pharmaceutical standards over rapid commercialisation, a pace that may frustrate operators but reassures insurers. “The next phase of cannabis growth will belong to operators that act first to manage risk. Those who build insured, transparent operations now will define standards, secure capital, and outpace slower competitors,” the report notes. The capital markets dimension amplifies this dynamic. Investors and lenders increasingly require comprehensive insurance as a financing condition. A cannabis operator seeking growth capital must demonstrate not just that it has insurance, but that its risk posture is strong enough to maintain coverage through scaling and market expansion. “The Risk Briefing provides great insights into the different risk mitigation best practices that operators can implement in order to shift the needle in the underwriting process,” Davey continued. The operators featured in the report demonstrate these principles. PHCANN International’s Macedonian facility employs 5-meter walls, licensed armed guards, over 200 cameras, and annual attack-response drills, with special forces response available within one minute. Linnea holds an EcoVadis silver medal, placing it among the top 15% of assessed companies worldwide on ESG criteria, monitoring emissions and recycling extraction waste into renewable energy. SOMAÍ Pharmaceuticals emphasises supplier financial viability: “Companies in financial trouble often cut corners, even unintentionally. We’re always transparent about our own financials with partners,” says CEO Michael Sassano. As insurance capacity expands in select markets, underwriters now have enough data to differentiate between well-managed and poorly-managed operators. Premium spreads will widen. Coverage restrictions will become more tailored. Operators with robust risk management will access broader coverage at lower cost, while those with weak governance will find themselves increasingly uninsurable. The word ‘cannabis’ once all but guaranteed rejection. Today, proving professionalism has become the requirement for protection. The Risk Briefing: Cannabis 2026 is available from Relm Insurance and Prohibition Partners. submitted by /u/markoj22 to r/MedicalCannabis_NI [link] [comments]

Hi everyone, I’m an international student currently based in the UK and trying to break into ESG / sustainability / environmental consulting at the entry level. I’ve been applying for graduate and junior roles (e.g., ESG analyst, sustainability consultant, environmental coordinator), but I’ve barely received any interviews so far. Before I keep sending more applications, I want to check whether there might be something fundamentally wrong with my CV or the way I position myself. My background: • Master’s degree related to environment & development • Some ESG-related internships (corporate sustainability, sustainable projects, research assistance) • Experience in environmental volunteering and communication • Interested in impact assessment, sustainability reporting, corporate sustainability, and green transition topics I know the ESG job market is super competitive, but I’m not sure whether: 1. My CV is not aligned with UK hiring standards 2. My achievements aren’t presented clearly enough 3. Or I’m applying to the wrong types of roles If anyone here is familiar with UK sustainability hiring or works in ESG consulting, I’d really appreciate it if you could take a look at my CV and let me know what could be improved （structure, keywords, focus, or anything else） Happy to anonymise any details if needed. Thanks in advance! submitted by /u/Dry-Green-1794 to r/Environmental_Careers [link] [comments]

https://preview.redd.it/1iwq5tfmz90g1.png?width=1778&format=png&auto=webp&s=6d07fc178ea6e4af515661958f57e9ec6e8cf33f Executive Summary Acutaas Chemicals Limited has crafted a leading transformation narrative within India's specialty chemicals sector. It has successfully pivoted from a pharmaceutical intermediates-focused business into a diversified, high-growth midcap company with strategic bets on battery additives and semiconductor materials. The Q2 FY26 results showcased 24% revenue growth and an impressive 89% profit surge, driven by operational excellence, disciplined capital expenditure, and expanding exports—all while maintaining a virtually debt-free balance sheet supported by robust long-term customer contracts. With a 15-year track record of compounding at ~25% annually, management guides for continued rapid growth as new product verticals ramp up, making Acutaas Chemicals a compelling case study in portfolio transformation, financial discipline, and multi-year investment potential. Part 1: The Business Transformation Story Acutaas Chemicals exemplifies one of the most instructive business transformation narratives in Indian specialty chemicals. The company is systematically transitioning from a single-sector manufacturer to a diversified player exposed to three megatrends: pharmaceutical CDMO, battery electrolyte additives, and semiconductor materials. The Strategic Shift The Problem: In FY20, the company's revenue was 97% dependent on pharmaceutical intermediates, creating significant sector concentration risk and limiting growth optionality. The Solution: Over 5-6 years, management executed a deliberate portfolio rebalancing without disrupting profitable core operations. Transformation Timeline Financial Year Pharma Intermediates Specialty Chemicals Strategic Focus FY20 97% 3% Build specialty chemicals foundation FY25 85% 15% Scale existing products, identify new verticals H1 FY26 83% 17% Launch battery additives, ramp semiconductor JV Investor Lesson: The best transformations are often gradual, not revolutionary. By maintaining profitability while building new foundations, the company significantly reduced execution risk. Part 2: Deconstructing Q2 FY26 Performance The quarterly results provide a masterclass in reading between the lines of financial statements. The Headline Numbers Revenue: ₹316 crore (+24% YoY) Net Profit: ₹72 crore (+89% YoY) Reported Operating Margin: 31% The Critical Analysis: Why Profit Grew 3.7x Faster Than Revenue This divergence demands a normalized analysis to identify exceptional items: Identified Exceptional Items: Gain on Consolidation/Revaluation: ₹16 crore from investment-related transactions (often recorded under Other Income or as a one-time gain). Foreign Exchange Gain: ₹1 crore benefit from currency movements. Adjusted Numbers (Conservative View): Normalized EBITDA Margin: ~25-26% (vs. reported 31%) True Operational Performance: Still strong, but not as exceptional as the headline numbers suggest. Investor Lesson: Master the art of normalizing financials. Always subtract one-time gains before comparing margins and use normalized earnings for a realistic valuation. Part 3: The Three Growth Engines Engine 1: CDMO Business (Pharmaceutical Intermediates) – The Proven Performer What It Is: Acutaas manufactures complex chemical intermediates for pharma companies, becoming an embedded, "sticky" supplier. Q2 FY26 Performance: Revenue of ₹262 crore (83% of total), growing 27% YoY. Long-term Target: ₹1,000 crore by FY28. Why It's "Sticky": High customer switching costs due to 1-2 year quality vetting and strict regulatory (cGMP) compliance. The EcoVadis Platinum Certificate places them in the top 1% of global CDMO partners. Engine 2: Battery Electrolyte Additives – The Growth Catalyst The Opportunity: To supply critical VC and FEC additives for lithium-ion batteries, filling a domestic import gap from China/Japan. The Project: Location: Jagdishpur, Uttar Pradesh Products: VC and FEC additives Capacity: 2,000 metric tons annually Investment: ₹180 crore Commercialization: Q4 FY26 (with full ramp-up estimated by Q2 FY27) De-risking Factors: Pre-booked demand via long-term supply agreements with multiple global customers. Management notes revenue is locked in per contracts, even if battery chemistries evolve. Engine 3: Semiconductor Materials – The Strategic Explorer The Joint Venture: IndChem in South Korea (Acutaas 75% : Korean Partner 25%). Product: Advanced organic chemical materials for semiconductor photoresists. Investment: ~₹25-30 crore from Acutaas' perspective. Timeline: Construction completion May 2026; commercialization H2 FY27. Strategic Rationale: Leverages Korean partner's expertise and customer relationships to enter the coveted Korean semiconductor supply chain, benefiting from geopolitical shifts away from Chinese dependency. Investor Lesson: A robust portfolio has a core (CDMO), a catalyst (Battery), and an explorer (Semiconductor). Each carries different risk/reward profiles and is funded accordingly. Part 4: Financial Health & Capital Allocation Discipline Balance Sheet Strength (H1 FY26) Metric Value Implication Net Debt ₹2 crore Essentially debt-free Cash Position ₹240 crore Strong war chest for capex Total Capex (FY26) ₹250 crore Pre-funded from operations; no equity dilution Debt-to-Equity ~0.01x One of the cleanest balance sheets in the sector Capex Allocation & Funding The ₹250 crore FY26 capex is front-loaded and fully funded internally: Battery Additives: ₹180 crore Semiconductor JV: ₹30 crore Maintenance: ₹40 crore Management guidance indicates no major capex is needed until FY28, protecting shareholders from dilution. Working Capital Optimization The Working Capital Cycle improved from 123 days (FY25) to 100 days (H1 FY26). This 23-day improvement signifies superior operational efficiency, effectively freeing up ~₹25 crore in cash on quarterly revenues of ~₹300 crore. Investor Lesson: Working capital optimization is "hidden cash generation." It often precedes profit growth and is a hallmark of operational maturity. Part 5: Understanding Valuation & Entry Strategy Current Valuation Context Stock Price: ₹1,765 (as of recent trading) Trailing P/E: ~64x 52-Week Range: ₹919 - ₹1,868 Is the Valuation Expensive? The Case for a Premium: 15-year 25% CAGR, margin expansion, strategic bets on megatrends, and a fortress balance sheet. High-quality peers trade at 40-50x P/E. The Case for Caution: The stock has rallied significantly, normalized margins are ~25-26%, and new ventures carry execution risk. A growth slowdown could lead to a sharp valuation de-rating. Suggested Valuation Framework For a company with Acutaas' profile (25% growth, 26% margins, debt-free), a fair P/E range is 45-55x. This implies a fair price range of approximately ₹1,400 - ₹1,600 based on conservative earnings assumptions. The current price of ₹1,765 sits at a premium to this range, demanding near-flawless execution. Investor Lesson: Premium valuations are only justified by premium execution. Monitor key metrics like revenue growth, normalized margins, and project timelines closely. Part 6: The Complete Investment Decision Framework Who Should Own This Stock? ✓ Right For: Long-term investors (3-5 year horizon), those bullish on India's EV/semiconductor growth, and investors who can tolerate quarterly volatility without panic selling. ✗ Not Right For: Short-term traders, deep-value investors demanding sub-40x P/E, or those uncomfortable with project execution risk. The Risk Scorecard Risk Severity Monitoring Metric Battery additives delay HIGH Quarterly progress on plant construction Margin compression MEDIUM Quarterly EBITDA margins (target: 26%+) Semiconductor JV underperformance MEDIUM JV completion and first customer orders by FY27 Competitive entry MEDIUM Market share gains in specialty chemicals Global slowdown impacting exports MEDIUM Core CDMO growth rate (target: 20%+ YoY) Part 7: Key Metrics to Track Each Quarter As an investor, monitor these execution metrics: Revenue Growth (YoY): Target: 25%+. Concern: Below 20%. Normalized EBITDA Margin: Target: 25-27%. Concern: Below 23%. Specialty Chemicals % of Revenue: Target: Growing trajectory toward 25%+. Working Capital Cycle (days): Target: 95-105 days. Capex Spend vs. Plan: Monitor if battery and semiconductor plants are on schedule. Free Cash Flow: Target: Positive, even with heavy capex. Customer Concentration: Target: Diversified (no single customer >15%). Part 8: The 3-Year Investment Timeline Quarters 1-4 (FY26-H1 FY27): The Construction Phase Focus: Battery plant commercialization (Q4 FY26), IndChem JV construction, core CDMO stability. Quarters 5-8 (H2 FY27-FY28): The Ramp-Up Phase Focus: Battery additives reaching 50-60% utilization, first revenue from IndChem, margin expansion. Quarters 9-12 (FY29 Onwards): The Normalization Phase Focus: New verticals contributing meaningfully, strong FCF generation post-capex. Part 9: The Investor's Checklist Before Buying Strategic Understanding Do I believe in the underlying EV and semiconductor megatrends? Do I understand the "sticky" nature of the CDMO business model? Can I differentiate between speculative capex and this pre-booked, de-risked capex? Financial & Risk Assessment Have I normalized the earnings to account for one-time items? Am I comfortable with the current P/E, and are my expectations aligned with a long-term hold? Am I prepared for potential stock price consolidation if project timelines slip by a quarter or two? Valuation & Temperament Would I be willing to buy more if the stock corrected to the ₹1,400-1,600 fair value range? Can I hold patiently through a 6-12 month period of sideways movement? Do I commit to monitoring quarterly results rather than the daily stock price? Part 10: Advanced Topic—Capital Allocation Discipline The management of Acutaas Chemicals has demonstrated remarkable capital discipline, a key reason for investor trust: No Dilution: Front-loaded capex is funded internally, despite premium valuations, preventing shareholder dilution. Minimal Debt: The company remains virtually debt-free even with a ₹250 crore capex outlay. Portfolio Pruning: Actively exited low-margin products to focus on high-ROIC businesses. Investor Lesson: Watch management's capital allocation decisions, not just their guidance. Acutaas' management has a proven track record of walking the walk. Conclusion: The Investment Thesis Summary Acutaas Chemicals is a high-quality business in transition, leveraging a stable CDMO core to fund strategic bets on high-growth verticals in batteries and semiconductors. Its debt-free balance sheet, disciplined capex, and long-term customer contracts provide a strong foundation for execution. The Bull Case Proven 15-year 25% CAGR. De-risked growth via pre-booked capacity. Geopolitical tailwinds for semiconductor supply chain entry. Strong operational leverage driving margin expansion. The Bear Case Premium valuation (64x P/E) requires flawless execution. New ventures are unproven and carry inherent execution risk. The stock is susceptible to de-rating if growth slows or margins contract. The Verdict & Strategy Acutaas Chemicals is a 5-star quality business trading at a 4-star price point. The current price of ₹1,765 appears to factor in near-perfect execution. The most prudent strategy is to wait for a market-led correction to the ₹1,400-1,600 range for an optimal entry. For existing investors with a long-term horizon and high conviction, holding through volatility is justified. For all investors, the key is to monitor execution against the quarterly metrics outlined above. Key Takeaway for Your Learning The true lesson from Acutaas Chemicals is the process of identifying a successful transformation: Identify the Theme: A company pivoting from mature to growth markets. Verify the Execution: Look for pre-booked revenue, not speculative capex. Assess Management: Prioritize capital allocation discipline over promotional guidance. Calculate Fair Value: Normalize earnings to see the true operational picture. Wait for Your Pitch: Premium businesses often offer better entry points during periods of short-term uncertainty or market weakness. Disclaimer: This analysis of Acutaas Chemicals Limited is provided solely for educational and informational purposes. It is not investment advice or a recommendation to buy, sell, or hold any securities. Please conduct your own independent research and consult a qualified financial advisor before making any investment decisions. submitted by /u/Ok_Bluebird_1032 to r/stock_trading_India [link] [comments]

Source Reuters News submitted by /u/Lion_1981 to r/Trends2Share [link] [comments]